Company profile
ELOXX PHARMACEUTICALS, INC.
NASDAQ:ELOXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EXALUREN | phase2 | — | 9 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04069260 | phase2 | terminated | 2019-08-02 | 2019-12-17 | Eloxx Pharmaceuticals, Inc. | A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis |
| NCT04126473 | phase2 | completed | 2019-11-05 | 2022-04-06 | Eloxx Pharmaceuticals, Inc. | A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele |
| NCT04135495 | phase2 | completed | 2019-11-25 | 2022-10-03 | Eloxx Pharmaceuticals, Inc. | A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele |
| NCT05448755 | phase2 | completed | 2022-11-28 | 2023-09-11 | Eloxx Pharmaceuticals, Inc. | A Study of ELX-02 in Patients With Alport Syndrome |
| NCT03776539 | phase1 | completed | 2019-01-04 | 2019-07-30 | Eloxx Pharmaceuticals, Inc. | A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02 |
FDA applications (0)
No records yet.